NCT01286831View on ClinicalTrials.gov

A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 18, 2010

Primary Completion Date

July 9, 2010

Study Completion Date

July 9, 2010

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

[14C]GW642444

Single 200μg dose of \[14C\]GW642444 given on Day 1.

Trial Locations (1)

9471 GP

GSK Investigational Site, Zuidlaren

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01286831 - A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444. | Biotech Hunter | Biotech Hunter